Drugs/NNS are/VBP frequently/RB prescribed/VBN to/IN patients/NNS with/IN the/DT aim/NN of/IN improving/VBG each/DT patient/NN 's/POS medical/JJ state/NN ,/, but/CC an/DT unfortunate/JJ consequence/NN of/IN most/JJS prescription/NN drugs/NNS is/VBZ the/DT occurrence/NN of/IN undesirable/JJ side/NN effects/NNS ./.
Side/NN effects/NNS that/WDT occur/VBP in/IN more/JJR than/IN one/CD in/IN a/DT thousand/CD patients/NNS are/VBP likely/JJ to/TO be/VB signalled/VBN efficiently/RB by/IN current/JJ drug/NN surveillance/NN methods/NNS ,/, however/RB ,/, these/DT same/JJ methods/NNS may/MD take/VB decades/NNS before/IN generating/VBG signals/NNS for/IN rarer/JJR side/NN effects/NNS ,/, risking/VBG medical/JJ morbidity/NN or/CC mortality/NN in/IN patients/NNS prescribed/VBN the/DT drug/NN while/IN the/DT rare/JJ side/NN effect/NN is/VBZ undiscovered/JJ ./.
In/IN this/DT paper/NN we/PRP propose/VBP a/DT novel/JJ computational/JJ meta/NN -/HYPH analysis/NN framework/NN for/IN signalling/NN rare/JJ side/NN effects/NNS that/WDT integrates/VBZ existing/VBG methods/NNS ,/, knowledge/NN from/IN the/DT web/NN ,/, metric/JJ learning/NN and/CC semi-supervised/VBN clustering/NN ./.
The/DT novel/JJ framework/NN was/VBD able/JJ to/TO signal/VB many/JJ known/JJ rare/JJ and/CC serious/JJ side/NN effects/NNS for/IN the/DT selection/NN of/IN drugs/NNS investigated/VBN ,/, such/JJ as/IN tendon/NN rupture/NN when/WRB prescribed/VBN Ciprofloxacin/NN or/CC Levofloxacin/NN ,/, renal/JJ failure/NN with/IN Naproxen/NNP and/CC depression/NN associated/VBN with/IN Rimonabant/NNP ./.
Furthermore/RB ,/, for/IN the/DT majority/NN of/IN the/DT drug/NN investigated/VBD it/PRP generated/VBD signals/NNS for/IN rare/JJ side/NN effects/NNS at/IN a/DT more/RBR stringent/JJ signalling/NN threshold/NN than/IN existing/VBG methods/NNS and/CC shows/VBZ the/DT potential/JJ to/TO become/VB a/DT fundamental/JJ part/NN of/IN post/NN marketing/NN surveillance/NN to/TO detect/VB rare/JJ side/NN effects/NNS ./.
